Naoya Sakamoto

High tryptophan 2,3-dioxygenase expression promotes lenvatinib resistance in hepatocellular carcinoma

Background Lenvatinib (LEN) is a key first-line therapy for advanced hepatocellular carcinoma (HCC), but intrinsic and acquired resistance limits its long-term efficacy. We aimed to identify novel mechanisms underlying LEN resistance and to explore clinically relevant biomarkers...